keyword
MENU ▼
Read by QxMD icon Read
search

Anoro

keyword
https://www.readbyqxmd.com/read/27853383/uk-specific-cost-effectiveness-of-tiotropium-olodaterol-fixed-dose-combination-versus-other-lama-laba-combinations-in-patients-with-copd
#1
Abigail Tebboth, Andrew Ternouth, Nuria Gonzalez-Rojas
OBJECTIVE: The aim of this study is to assess the cost-effectiveness of other long-acting muscarinic antagonist + long-acting β2 agonist combinations in comparison with Spiolto(®) Respimat(®) (tiotropium + olodaterol fixed-dose combination [FDC]) for maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. METHODS: A previously published individual-level Markov model was adapted for the perspective of the UK health care system, in line with recommendations from the National Institute for Health and Care Excellence...
2016: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/27578968/correct-usage-ease-of-use-and-preference-of-two-dry-powder-inhalers-in-patients-with-copd-analysis-of-five-phase-iii-randomized-trials
#2
John H Riley, Maggie Tabberer, Nathalie Richard, Alison Donald, Alison Church, Stephanie S Harris
BACKGROUND: Handheld inhalers are used to deliver treatment for COPD. Incorrect usage leads to suboptimal disease control. Complex treatment regimens and use of multiple inhalers may reduce patient compliance. The Anoro Ellipta™ dry powder inhaler (DPI) simultaneously delivers umeclidinium bromide (UMEC) and vilanterol (VI) without coformulation being required. AIM: To assess the correct usage and ease of use of the Ellipta™ DPI administering UMEC/VI and to compare patient preference for Ellipta™ with the HandiHaler(®) through exploratory analyses of patient and observer questionnaires in five Phase III studies...
2016: International Journal of Chronic Obstructive Pulmonary Disease
https://www.readbyqxmd.com/read/25398674/umeclidinium-vilanterol-a-review-of-its-use-as-maintenance-therapy-in-adults-with-chronic-obstructive-pulmonary-disease
#3
REVIEW
Hannah A Blair, Emma D Deeks
Umeclidinium/vilanterol (Anoro(®) Ellipta™; Laventair™) is an inhaled fixed-dose combination of a long-acting muscarinic receptor antagonist and a long-acting β2-adrenoceptor agonist. It is available in several countries, including Japan, the USA, Canada and those of the EU, where it is indicated for oral inhalation in adults with chronic obstructive pulmonary disease (COPD). Umeclidinium/vilanterol is administered once daily using the Ellipta™ multi-dose dry powder inhaler, which is regarded as easy to use...
January 2015: Drugs
https://www.readbyqxmd.com/read/25382021/umeclidinium-bromide-vilanterol-for-the-treatment-of-chronic-obstructive-pulmonary-disease
#4
REVIEW
Maria Gabriella Matera, Paola Rogliani, Barbara Rinaldi, Mario Cazzola
A solid scientific rationale and an increasing body of clinical evidence fully support the use of an antimuscarinic agent combined with a β-agonist in chronic obstructive pulmonary disease. In this article, we focus on the development of an inhaled fixed dose combination (FDC) of two 24-h bronchodilators, umeclidinium bromide and vilanterol (UMEC/VI) (ANORO). Several pivotal clinical trials have documented the impact of this combination on lung function and other outcome measures such as quality of life, dyspnea, rescue medication use and exercise capacity, with no clinically meaningful treatment-related changes in vital signs or clinical laboratory parameters...
January 2015: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/24736248/anoro-ellipta-an-inhaled-umeclidinium-vilanterol-combination-for-copd
#5
REVIEW
(no author information available yet)
No abstract text is available yet for this article.
April 14, 2014: Medical Letter on Drugs and Therapeutics
https://www.readbyqxmd.com/read/24696868/umeclidinium-vilanterol-fixed-dose-combination-for-copd
#6
J Gras
Chronic obstructive pulmonary disease (COPD) mortality is projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly tobacco smoke exposure. Umeclidinium/vilanterol at 62.5/25 μg is the fixed-dose combination of a long-acting antimuscarinic agent and a long-acting β2-adrenoceptor agonist that administered as dry powder by inhalation was developed for the maintenance treatment of COPD. The combination demonstrated its efficacy in phase III studies where the amelioration of lung function translated into subjective symptomatic improvements...
March 2014: Drugs of Today
https://www.readbyqxmd.com/read/24669177/pharmaceutical-approval-update
#7
Marvin M Goldenberg
Simeprevir (Olysio) for chronic hepatitis C infection; coagulation Factor XIII A-subunit (recombinant) (Tretten) for bleeding prevention in congenital Factor XIII A-subunit deficiency; and umeclidinium and vilanterol inhalation powder (Anoro Ellipta) for chronic obstructive pulmonary disease.
February 2014: P & T: a Peer-reviewed Journal for Formulary Management
https://www.readbyqxmd.com/read/24532124/umeclidinium-vilanterol-first-global-approval
#8
Lesley J Scott, Philip Hair
Umeclidinium/vilanterol (Anoro™ Ellipta™ [USA; Canada; proposed Japan]; Anoro™ [proposed EU]), an inhaled fixed-dose combination of a long-acting muscarinic antagonist and a long-acting β2-adrenergic agonist, is indicated for once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Umeclidinium/vilanterol received its first global approval in this indication in the USA and has subsequently been approved for use in the same indication in Canada, with submissions for regulatory approval in patients with COPD under review elsewhere, including in Europe and Japan...
March 2014: Drugs
https://www.readbyqxmd.com/read/20022614/anti-annexin-a5-antibodies-in-women-with-spontaneous-pregnancy-loss
#9
COMPARATIVE STUDY
Jaume Alijotas-Reig, Raquel Ferrer-Oliveras, María José Rodrigo-Anoro, Inmaculada Farran-Codina, Elisa Llurba-Olivé, Miquel Vilardell-Tarres, Manel Casellas-Caro
BACKGROUND AND OBJECTIVE: The aim was to evaluate the role of anti-annexin A5 (anti-ANXA5) antibodies as risk factor for recurrent miscarriage (RM) and unexplained fetal loss (UFL). PATIENTS AND METHODS: Retrospective, cohort study. SETTING: Vall d'Hebron University Hospital. SUBJECTS: 122 women, in two groups: STUDY GROUP: 54 women with RM/UFL and control group: 68 pregnant without RM/UFL. INTERVENTION: Antiphospholipid, mainly anti-ANXA5 antibody analysis...
April 10, 2010: Medicina Clínica
https://www.readbyqxmd.com/read/19296946/anti-beta-2-glycoprotein-i-and-anti-phosphatidylserine-antibodies-in-women-with-spontaneous-pregnancy-loss
#10
Jaume Alijotas-Reig, Raquel Ferrer-Oliveras, Maria José Rodrigo-Anoro, Immaculada Farran-Codina, Luis Cabero-Roura, Miquel Vilardell-Tarres
OBJECTIVE: To evaluate the role of anti-beta(2)-glycoprotein-I (anti-beta(2)GPI-ab) and anti-phosphatidylserine (aPS-ab) antibodies as a risk factor in both recurrent miscarriage (RM) and unexplained fetal losses (UFL). DESIGN: Retrospective, cohort study. SETTING: Vall d'Hebron University Hospital, Barcelona, Spain. PATIENT(S): 122 pregnant women divided in two groups: study group of 54 women with RM and/or UFL and control group of 68 pregnant without RM history...
May 1, 2010: Fertility and Sterility
https://www.readbyqxmd.com/read/18022242/bloodstream-infections-in-adults-importance-of-healthcare-associated-infections
#11
COMPARATIVE STUDY
J Vallés, E Calbo, E Anoro, D Fontanals, M Xercavins, E Espejo, G Serrate, N Freixas, M A Morera, B Font, F Bella, F Segura, J Garau
OBJECTIVE: The objective of this study was to evaluate the characteristics of bloodstream infections occurring among outpatients having recent contact with the health care system compared to hospital and community-acquired infections. METHODS: Prospective observational cohort study of adult patients with bloodstream infections at three teaching hospitals. Bloodstream infection was defined as hospital-acquired if the first positive blood culture was performed more than 48 h after admission...
January 2008: Journal of Infection
https://www.readbyqxmd.com/read/15535008/-factors-related-to-experiencing-respiratory-failure-in-cases-of-opiate-overdose-for-which-care-was-provided-in-an-open-setting-barcelona-spain
#12
Manel Anoro, Enrique Ilundain, Rosa Rodriguez, Lali Rossell, Begoña Iglesias, Caterina Guinovart, Mercedes Gabari
BACKGROUND: To determine the factors associated with respiratory arrest in opiate overdoses (coma, pupillary miosis, respiratory depression, and response to naloxone) among injecting drug users in the Can Tunis quarter of Barcelona. METHODS: We ran a transversal observational study where all overdoses assisted between March, 2001 and June, 2002. After overdose treatment, data were collected using a standard questionnaire, including: patients' sociodemographic data, opiate and other substances' use prior to overdose, clinical signs and symptoms presented, and medical intervention received, by way of a standardised questionnaire...
September 2004: Revista Española de Salud Pública
https://www.readbyqxmd.com/read/12628151/-persistence-of-antibodies-three-years-after-vaccination-with-the-23-valent-pneumococcal-vaccine
#13
M Campins Martí, J Casal Lombos, D Tarragó Asensio, M J Rodrigo Anoro, A Allepuz Palau, L Callís Bracons
OBJECTIVE: To study the persistence of antibodies after primary immunization with the 23-valent pneumococcal vaccine in children with nephrotic syndrome. METHODS: Sera from 14 of 26 children with nephrotic syndrome were obtained 3 years after vaccination. We used an ELISA method to measure IgG antibody levels to pneumococcal serotypes 14, 23F, 3 and 6B. Antibody levels before vaccination, 1 month and 3 years after vaccination were compared. RESULTS: Significant increases in specific antibody concentrations were observed 30 days after vaccination for all serotypes except serotype 3...
February 2003: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría (A.E.P.)
https://www.readbyqxmd.com/read/11003897/-immunogenicity-of-the-23-valent-pneumococcal-vaccine-in-children-with-chronic-renal-disease
#14
M Campins Martí, M J Rodrigo Anoro, L Callís Bracons, N Pinart Pons, M J Cruz Carmona, J de Gracia Roldán, M Miravitlles Fernández
OBJECTIVE: To study the immunogenicity of the 23-valent pneumoccal vaccine in children with chronic renal disease and in those with nephrotic syndrome, and to compare it with the response in healthy children. METHODS: The vaccine was administered to 150 children aged 2-18 years: 113 with renal diseases (26 with nephrotic syndrome, 23 with severe grades of vesicoureteral reflux, 16 with chronic renal insufficiency, 6 renal transplant recipients, 6 requiring dialysis and 36 with other renal diseases) (group 1) and 37 healthy (group 2)...
March 2000: Anales Españoles de Pediatría
https://www.readbyqxmd.com/read/10814132/1-3-dipolar-cycloaddition-of-furfuryl-nitrones-with-acrylates-a-convenient-approach-to-protected-4-hydroxypyroglutamic-acids
#15
P Merino, S Anoro, S Franco, F L Merchan, T Tejero, V Tuñon
No abstract text is available yet for this article.
March 10, 2000: Journal of Organic Chemistry
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"